Search clinical trials for: Metastatic breast cancer

Total 89160 results

Washington University School of Medicine
United States Department of Defense; Aclaris Therapeutics, Inc.

Not yet recruiting

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer

United States
ABSCINT NV/SA

Not yet recruiting

HER2 Targeted Molecular Imaging in mBC Using 68Ga-ABS011 (HERMIA)

Metastatic Breast Cancer

Belgium
Wuhan Union Hospital, China

Recruiting

Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer

Triple-negative Breast Cancer | Cadonilimab

China
Puma Biotechnology, Inc.

Not yet recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)

Metastatic Breast Cancer | Recurrent Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer

United States
Universitaire Ziekenhuizen KU Leuven
Eli Lilly and Company; Kom Op Tegen Kanker; Teva Pharma

Recruiting

Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer (ABBICAR)

Triple Negative Breast Neoplasms

Belgium
Fudan University

Recruiting

Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer

Breast Cancer

China
Filipa Lynce, MD
Merck Sharp & Dohme LLC; Zentalis Pharmaceuticals

Not yet recruiting

A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined With Carboplatin and Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer (ZAP-IT)

Breast Cancer | Triple Negative Breast Cancer | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor Negative Malignant Tumor Breast Triple

United States
Centro di Riferimento Oncologico - Aviano

Not yet recruiting

Permanence of Indocyanine Green in Axillary Lymph Nodes 3 Weeks After Subdermal Injection in Patients With Breast Cancer and Metastatic Lymph Nodes (FLUO)

Breast Cancer

Italy
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer

HR+HER2- Breast Cancer

China
Aarhus University Hospital
Danish Cancer Society

Recruiting

The FEMA Study: Feasibility of Exercise in Patients With Metastatic Breast Cancer and Adiposity (FEMA)

Metastatic Breast Cancer | Adiposity | Estrogen-receptor-positive Breast Cancer

Denmark
Fudan University

Recruiting

Abemaciclib, Palbociclib or Dalpiciclib Combined With Endocrine Therapy as First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Breast Cancer

China
Fudan University

Recruiting

Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Breast Cancer

China
European Institute of Oncology

Recruiting

A Qualitative Study on Treatment Adherence in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

Italy
The Netherlands Cancer Institute
Hoffmann-La Roche

Not yet recruiting

NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial (TONIC-3)

Metastatic Breast Cancer
Helwan University

Not yet recruiting

Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients. (Palbociclib)

Metastatic Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Hormone-receptor-positive Breast Cancer
Nuvation Bio Inc.

Recruiting

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Pancreatic Cancer | Advanced Solid Tumor | HER2-negative Breast Cancer | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Platinum-resistant Ovarian Cancer (PROC)

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer

China
Boehringer Ingelheim

Not yet recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Metastatic Breast Cancer | Esophageal Adenocarcinoma | Metastatic Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma
Emory University
National Cancer Institute (NCI)

Not yet recruiting

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
European Institute of Oncology

Recruiting

Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies. (POSITive)

Melanoma | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Lung Cancer | Lung Metastases | Liver Metastases | Urothelial Carcinoma

Italy
Thomas Jefferson University

Recruiting

An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Breast Carcinoma

United States
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

HER2-positive Breast Cancer

China
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Breast Neoplasms

Israel
Zhejiang Cancer Hospital

Not yet recruiting

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

Metastatic Breast Cancer

China
N.N. Petrov National Medical Research Center of...

Recruiting

Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer

Oligometastatic Disease | HER2-positive Metastatic Breast Cancer

Russian Federation
Gustave Roussy, Cancer Campus, Grand Paris
Daiichi Sankyo

Recruiting

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd (ICARUSBREAST02)

Advanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast Carcinoma

France
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Triple Negative Breast Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

First-line Treatment | HER2-positive Metastatic Breast Cancer

China
Pliant Therapeutics, Inc.

Recruiting

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Metastatic Solid Tumor

United States
GeneMedicine Co., Ltd.

Recruiting

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Malignant Melanoma

Korea, Republic of
NiKang Therapeutics, Inc.

Recruiting

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

Small Cell Lung Carcinoma | Gastric Cancer | Ovarian Neoplasms | Ovarian Cancer | Solid Tumor | Endometrial Neoplasms | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumor | Endometrial Cancer | Small-cell Lung Cancer | Platinum-resistant Ovarian Cancer | Ovarian Carcinoma | Solid... and other conditions

United States
Reshma L. Mahtani, D.O.
Gilead Sciences

Not yet recruiting

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC (SERIES)

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Hormone-receptor-positive Breast Cancer | Human Epidermal Growth Factor 2 Low Breast Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | Estrogen Receptor-Positive Breast Carcinoma

United States
Valerio Therapeutics

Recruiting

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

Breast Cancer | Prostate Cancer | Advanced or Metastatic Solid Tumors | Recurrent Ovarian Cancer

United States
BeiGene

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Hormone Receptor Positive Malignant Neoplasm of Breast | HER2-negative Breast Cancer | Hormone-receptor-positive Breast Cancer

China
National Cancer Institute (NCI)

Recruiting

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Breast Cancer | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Gastrointestinal Cancer | Genitourinary Cancer | Metastatic Solid Cancers

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Not yet recruiting

TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer

Breast Cancer | Neoplasm, Breast | Malignant Neoplasm of Breast | Breast Tumor | Mammary Cancer | Mammary Neoplasms, Human | Tumor, Breast | Mammary Neoplasm

United States
Novartis Pharmaceuticals

Not yet recruiting

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

Breast Cancer
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Breast Cancer Stage IV | Locally Advanced Breast Cancer | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast Carcinoma

United States
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial

Breast Cancer

China
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer: Correlation to Therapeutic Efficacy of Cycline-Dependent Kinase Inhibitors(CDK4/6) as First Line Treatment. CYCLHER Study (CYCLHER)

Advanced Breast Carcinoma

Italy
H. Lee Moffitt Cancer Center and Research Institute
Gilead Sciences

Not yet recruiting

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Breast Cancer | Triple Negative Breast Cancer

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Recruiting

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Cervical Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Renal Pelvis Cancer | Urinary Bladder Neoplasm | Recurrent...

United States
Regina Elena Cancer Institute
Fondazione Policlinico Universitario Agostino Gemelli IRCCS; Catholic University... and other collaborators

Recruiting

Biomarkers of Efficacy and Tolerability of Sacituzumab-Govitecan in the Treatment of Patients With Triple-negative Breast Cancer in the Metastatic Phase: Prospective Multicenter Real-world Study (BIO-PROSA)

Breast Cancer

Italy
SOLTI Breast Cancer Research Group

Not yet recruiting

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan (ACROSS-TROP2)

Breast Cancer Stage IV

Spain
Hospital Israelita Albert Einstein
AstraZeneca

Recruiting

Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil

Breast Cancer

Brazil
Gene Solutions

Recruiting

Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.

Breast Cancer | Gastric Cancer | Colorectal Cancer | Non Small Cell Lung Cancer | Advanced Cancer | Liver Cancer | Immune Checkpoint Inhibitor

Vietnam
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer

Breast Cancer
Laura Huppert, MD, BA
Ambrx, Inc.

Not yet recruiting

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Triple Negative Breast Cancer | Hormone Receptor Positive Breast Carcinoma | HER2 Low Breast Carcinoma | Hormone-receptor-positive Breast Cancer

United States
Mayo Clinic

Recruiting

Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer

Breast Carcinoma | Recurrent Breast Carcinoma | Metastatic Breast Carcinoma

United States

Search clinical trials for: Metastatic breast cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations